ReviewProbiotics and antimicrobial proteins2026
Designing the Next Generation of Endolysins: A Triple Strategy Integrating Bioinformatics Mining, Engineering Modification and Encapsulation Formulation.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phage-Derived Endolysins TargetingAntibiotics (Basel, Switzerland) · 2026Review
- Bacteriophage lysins: a promising strategy for combating foodborne pathogens in food safety.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The intensifying challenge of antimicrobial resistance (AMR) has outpaced traditional antibiotic discovery, leading the World Health Organization to call for the rapid exploration of alternative therapeutic options. Endolysins-phage-encoded peptidoglycan hydrolases-exhibit potent bacteriolytic activity against multidrug-resistant pathogens and show minimal propensity for resistance development. However, their clinical translation remains hindered by several critical barriers, including resource-intensive discovery processes, limited permeability through the outer membrane of Gram-negative bacteria, and various chemical, physical, and immunological challenges. In this review, we systematically summarize the fundamental characteristics of endolysins and integrate a tripartite strategy to enhance their therapeutic potential: bioinformatics-based pre-screening mining stage, mid-stage optimization stage of engineered modifications and post-enhancement stage combining encapsulation and formulation. Challenges inherent to each stage are critically analyzed, and future directions for endolysin development are discussed. Such multiple strategies provide a comprehensive roadmap for overcoming current barriers and accelerating the development of next-generation endolysin-based therapies against AMR.
Indexed as
Identifiers
41505076What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.